NESACAINE-MPF
Details
- Status
- Prescription
- First Approved
- 1955-03-11
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
NESACAINE-MPF Approval History
What NESACAINE-MPF Treats
1 indicationsNESACAINE-MPF is approved for 1 conditions since its original approval in 1955. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Local Anesthesia
Drugs Similar to NESACAINE-MPF
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
NESACAINE-MPF FDA Label Details
ProIndications & Usage
FDA Label (PDF)Chloroprocaine hydrochloride injection 2% and 3%, in single dose vials, without methylparaben preservative, without EDTA, is indicated for the production of local anesthesia by infiltration, peripheral and central nerve block, including lumbar and caudal epidural blocks. Chloroprocaine hydrochloride injection is not to be used for subarachnoid administration.
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.